Serum transaminases during salicylate therapy

Area of Science:

• Pediatric Rheumatology
• Clinical Biochemistry
• Hepatology

Background:

• Chronic polyarthritis and dermatomyositis are inflammatory conditions affecting children.
• Elevated liver enzymes (transaminases) can be a sign of liver dysfunction.
• Salicylate therapy is sometimes used for inflammatory conditions.

Purpose of the Study:

• To investigate the relationship between salicylate levels and transaminase levels in pediatric patients.
• To determine if elevated transaminases in these patients are linked to salicylate dosage.
• To assess the reversibility of elevated transaminases upon reduction of salicylate levels.

Main Methods:

• Monitoring serum transaminase and salicylate levels in juvenile patients with chronic polyarthritis and dermatomyositis.
• Observing changes in transaminase levels following reduction of salicylate dosage.
• Assessing other indicators of liver function, including alkaline phosphatase.

Main Results:

• 8 out of 32 juvenile patients with chronic polyarthritis and 1 with dermatomyositis had elevated transaminases.
• In these patients, salicylate levels were consistently above 35 mg/100 ml.
• Reducing salicylate levels led to a rapid decrease in serum transaminases.
• Most children showed no other signs of liver dysfunction, though three had elevated alkaline phosphatase.
• One adult patient with mild cirrhosis also showed elevated transaminases.

Conclusions:

• Elevated serum transaminases in pediatric patients with chronic polyarthritis and dermatomyositis may be associated with high salicylate levels.
• Salicylate-induced hepatotoxicity appears to be reversible upon dose reduction.
• Careful monitoring of liver function is recommended for pediatric patients on salicylate therapy.